研究業績 2026年

  • Tsuru I, Taguchi S, Tanaka R, Kawai T, Kaneko T, Nakamura Y, Miyauchi Y, Hoshina H, Obinata D, Koshiba M, Shiozaki M, Takahashi J, Kano M, Naito A, Suda S, Noda M, Sugiyama N, Tanaka T, Uemura Y, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada Y, Sato Y, Yamada Y, Nishimatsu H, Murata T, Takahashi S, Takada T, Akiyama Y, Takahashi S, Fujimura T, Fukuhara H, Nakagawa T, Kume H. Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study. Jpn J Clin Oncol 2026 in press. [open access]
  • Suzuki Y, Oriyama T, Yamamoto T, Hatano M, Amiya E, Tsuji M, Bujo C, Takeda N, Ando M, Ono M, Takada T. Serum KL-6 and eGFR predict everolimus-associated KL-6 elevation in heart transplant recipients: a retrospective observational study. J Pharm Health Care Sci 2026 in press. [open access]
  • Yamaguchi R, Yamamoto T, Harada S, Shibuya M, Mizoguchi M, Higurashi Y, Miyata Y, Ogiue N, Tsutsumi T, Takada T. Optimal vancomycin AUC24/MIC ratio for predicting clinical outcomes in patients with glycopeptide-susceptible Enterococcus faecium bacteremia. Eur J Clin Microbiol Infect Dis 2026 45(7):1929-1939. [open access]
  • Yamamoto S, Inoue K, Yasujima T, Takei H, Yamashiro T, Asai K, Matake I, Uchiyama S, Ohta K, Kishimoto H, Higuchi K, Anayama H, Asao Y, Hirabayashi H, Amano N, Shimizu T, Takada T, Tamura T, Wakai K, Kawamura Y, Nakayama A, Toyoda Y, Matsuo H, Yuasa H. SLC52A1 Is a Neofunctionalized Primate Urate Transporter Enabling Intestinal Urate Secretion. J Biol Chem 2026 302(4):111310. [open access]
  • Yagi H, Akazawa H, Liu Q, Ito SM, Umei M, Kadowaki H, Matsuoka R, Shindo A, Okamura S, Ueda T, Saga-Kamo A, Ueda K, Takeda N, Takada T, Komuro I. Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Progressive Aortic Dilatation in Marfan Syndrome. Arterioscler Thromb Vasc Biol 2026 46(1):132-144. [abstract]
  • Miyata H, Morimoto K, Hosoya T, Toyoda Y, Hosoyamada M, Takada T. Renal nicotinate handling by URAT1: hidden benefits of URAT1-targetting uricosuric agents. Kidney360 2026 7(1):187-189. [open access]
  • Kawai T, Maki K, Taguchi S, Fujii Y, Tanaka T, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada D, Yamada Y, Takada T, Nakagawa T, Kume H. Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer. Prostate 2026 86(3):297-306. [open access]